Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -6.65
- Piotroski Score 3.00
- Grade Neutral
- Symbol (MRSN)
- Company Mersana Therapeutics, Inc.
- Price $2.12
- Changes Percentage (-4.07%)
- Change -$0.09
- Day Low $2.06
- Day High $2.29
- Year High $6.28
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $3.00
- High Stock Price Target $3.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.12
- Trailing P/E Ratio -1.91
- Forward P/E Ratio -1.91
- P/E Growth -1.91
- Net Income $-171,670,000
Income Statement
Quarterly
Annual
Latest News of MRSN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
The CEO mentions that specific patient numbers and biomarker data for XMT-1660 will be shared later this year. The company is exploring more frequent dosing schedules and assessing prior treatment his...
By Yahoo! Finance | 4 days ago
